The ongoing H1N1 flu pandemic and the intensive care community: challenges, opportunities, and the duties of scientific societies and intensivists by Moreno, Rui P. et al.
Rui P. Moreno
Andrew Rhodes
Jean-Daniel Chiche
The ongoing H1N1 ﬂu pandemic and the
intensive care community: challenges,
opportunities, and the duties of scientiﬁc
societies and intensivists
Received: 1 October 2009
Accepted: 6 October 2009
Published online: 20 October 2009
 The Author(s) 2009. This article is published with open access at
Springerlink.com
R. P. Moreno ())
Unidade de Cuidados Intensivos Polivalente,
Hospital de St. Anto ´nio dos Capuchos,
Centro Hospitalar de Lisboa Central, E.P.E,
Lisbon, Portugal
e-mail: r.moreno@mail.telepac.pt
Tel.: ?351-3153784
A. Rhodes
Department of Intensive Care Medicine,
St George’s Healthcare NHS Trust,
London SW17 0QT, UK
e-mail: andyr@sgul.ac.uk
Tel.: ?44-2087255699
J.-D. Chiche
Service de Re ´animation Me ´dicale,
Ho ˆpital Cochin (AP-HP), Universite ´ Paris Descartes,
Unite ´ Inserm U567,
75014 Paris, France
e-mail: jean-daniel.chiche@cch.aphp.fr
Tel.: ?33-1-58412739
This year has brought a new challenge to Intensive Care
Medicine. The current inﬂuenza A (H1N1) pandemic may
have a disproportionate effect on the provision of Inten-
sive Care services in Europe. These challenges cause
many anxieties for practicing clinicians, both as to what to
expect, how to practice and what support or help they will
be given. In this statement from the European Society of
Intensive Care Medicine (ESICM), we aim to describe
some of the facts, the fears and the areas where scientiﬁc
societies can help to improve our understanding of these
problems and at the same time reduce the impact of these
issues for our members and their patients.
The facts
In 2009, a new acute respiratory disease emerged in
Mexico, secondary to a swine-origin inﬂuenza A (H1N1)
virus (S-OIV). Public health agencies did their best to
contain the dissemination of the disease; however,
unfortunately these efforts failed, and on the 11 June, the
World Health Organization (WHO) declared the ﬁrst ﬂu
pandemic since 1968. The disease spread rapidly across
the globe. In the southern hemisphere, Intensive Care
faced an unprecedented challenge with as many as 25% of
all ICU patients in Australia and New Zealand having
either suspected or conﬁrmed S-OIV by the middle of
August [1]. In the Northern hemisphere, the ﬁrst wave of
the pandemic had a very heterogeneous impact, with the
USA, Canada, England and Spain being especially
affected. By the end of August, virtually all countries had
reported cases, and many had also reported deaths.
Very early, it became clear that a signiﬁcant number of
deathswereprecededorcausedbyrapidlydevelopingacute
respiratory failure often refractory to conventional
mechanical ventilation. Although the vast majority of
individualshadamildillness,similartoseasonalﬂu,itwas
observedthatcertaingroupsnotusuallyatincreasedriskof
complications or death from seasonal inﬂuenza were at
special risk for S-OIV. These groups include the pregnant
or recent postpartum [2], the obese and the young [3–5].
Three predominant syndromes have been reported [1, 6]t o
be associated with life-threatening situations:
– acute viral pneumonitis with bilateral pulmonary
inﬁltrates [‘‘ﬂu A’’-associated acute respiratory distress
syndrome (FLAA-ARDS)];
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– viral exacerbation of airﬂow limitation.
FLAA-ARDS, the most commonly described of these
syndromes, was associated with a very high mortality.
Multiple organ dysfunction syndrome (MODS) developed
rapidly in up to 75% of the patients [6], despite the fact
that most of these died due to refractory hypoxaemia
apparently resistant to the use of measures such as high
frequency oscillation and extra-corporeal membrane
oxygenation (ECMO) [7]. Approximately half went on to
develop life-threatening super-added infections [6], which
were especially common in those with co-existing morbid
obesity, diabetes mellitus, immunosuppression, malig-
nancy and chronic lung disease [1].
The fears
Previous inﬂuenza pandemics occurred in 1918 (H1N1
strain), 1957 (H2N2 strain) and 1968 (H3N2 strain),
resulting in very signiﬁcant levels of morbidity and
mortality. This was especially the case in the pandemic of
1918–1919, which caused major social disruption fol-
lowing the First World War. Today, we can be more
optimistic as this current pandemic is unique in respect of
two important issues:
1. The state of public preparedness for a pandemic is well
in excess of anything previously seen. This has
developed following the emergence of severe acute
respiratory syndrome (SARS) [8] and the threat of
avian ﬂu (H5N1). Major plans have therefore been
developed in many countries that could be now
implemented [9, 10].
2. Since the previous pandemics, Intensive Care Medi-
cine has evolved to enable the treatment of very sick
patients presenting with an acute respiratory illness,
and we have now new and better antibiotics and
antivirals. Modern techniques of mechanical ventila-
tion together with protocols for the support and
treatment of multiple organ failure may reduce the
overall mortality of these conditions.
Despite the existing plans, the biggest unknown factor
remainstheoverallimpactthatthepandemicwillhaveboth
on the health and on the economy. Epidemiologists have
been modeling likely scenarios, but the models are notori-
ously inaccurate early on in a pandemic phase [11]. Using
anattackraterangingfrom10to30%ofthepopulationwith
ahospitaladmissionratecloseto1%andacase-fatalityrate
close to 0.14%, as in seasonal ﬂu (an hypothesis supported
by preliminary data [1]), the pandemic may have a major
impact on health services and ICM in particular. Some
models have predicted critical care demand at the peak
surge of the pandemic to be well in excess of 100% of
available facilities, even in the most developed countries
[11]. This is of considerable concern to practicing Intensi-
vists. Increasing intensive care support by a factor of two
without additional skilled and trained specialists and
without the usual range or technical facilities and support
services may well force us to ventilate more patients than
normal, but this would not be ‘quality critical care.’ If this
increased surge was to occur, then the numbers of patients
presentingwouldbewellinexcessoftheavailablecapacity
to provide them with quality care. This will necessitate
triage. The ethics of triage have been discussed several
times [12–15], but the concerns as to whether the ethical or
legal framework will ultimately support clinicians faced
with these tribulations remain. Practicing for a greater
good,ratherthanwhatisbestforanindividualpatient,may
be the pragmatic answer to the problem, but clinicians are
rightlyconcernedthatthismayleadtofuturecomplaintand
legalorprofessionalcensure.Unfortunately,manynational
governmental authorities have failed to address these con-
cerns with clear and open guidance.
The resources
In response to these uncertainties, many groups have
started to develop more sophisticated plans based on
better data. These plans are now being fed from data
acquired by global registries, such as the H1N1 registry,
commissioned and developed by the European Society of
Intensive Care Medicine (www.h1n1registry.org). Data
from this registry will allow real-time trends to be seen
and witnessed, which hopefully will enable us to adjust
our resources and facilities to be able to cope with a
predicted second surge of the disease. Ultimately, more
sophisticated analysis will allow us to develop more
accurate models for future pandemics that may occur.
In these models, we need to take into account the
speciﬁcities of this pandemic and the fact that it predomi-
nantly affects the young. In many countries the numbers of
pediatricintensivecare(PICU)bedsareatalevelfarbelow
thatoftheadultspecialty.Inaddition,PICUhascentralized
its service in many countries, with the implication that
many smaller hospitals no longer have signiﬁcant skill
basesorequipmenttocareforthesechildren.Thismaywell
resultinasigniﬁcantnumberofyoungpatientsbeingcared
for in an adult environment. Even disregarding the prob-
lems of putting young patients into an adult unit, the skill
and knowledge gap is huge, and this needs to be rapidly
addressed to prepare for this eventuality. The close links
that exist between the ESICM and the European Society of
Paediatric and Neonatal Intensive Care (ESPNIC) will
undoubtedly prove to be an important asset to mount a
coordinated and efﬁcient response to the current threat.
Even today, many questions remain unanswered, and
our understanding of many facets of this pandemic is poor
2006[16]. We still know little with regards the pathogenesis or
the optimal treatment of the disease. The deﬁnition of
patients-at-risk remains unclear, and the indications, opti-
mal doses and duration of therapy are not certain. We need
betterinformationwithregardstotheimpactofthevaccine
in the spread of the pandemic, the use of anti-viral agents,
the risks and beneﬁts of steroids or the importance of pre-
emptive antimicrobial therapy. To answer those questions
(and many others), several registries and collaborative
studies have been initiated. On the back of these registries,
together with the established trials groups [such as the
European Critical Care Research Network (ECCRN) Trial
Group], we hope to be able to initiate and coordinate col-
laborative interventional research that will increase our
knowledge base of this problem.
We contend that such research efforts can and must
happen in real time, as the pandemic develops. Indeed,
history has shown us that when faced with the most severe
of challenges, we usually manage to cope. This often
takes courage as well as ingenuity and innovation.
Despite the adversities faced and the challenges of
working long and stressful shifts, research continues and
knowledge base advances. During the SARS crisis in
2002 [17, 18], guidelines for treatment were generated as
fast as the disease spread [19], and research output was
maintained or even increased. Facing the threat of being
infected themselves, clinical teams, often overwhelmed
with clinical duties, kept collecting and analyzing data,
enabling them to test the best approaches to decrease the
morbidity and the mortality of SARS. We would like to
thank publicly all of our colleagues that have used their
time and efforts to increase our knowledge of this disease,
in order to minimize its worldwide impact and to achieve
better outcomes for all of our patients. We are certain that
the same will happen now.
Despite all of our doubts and the existence of huge
heterogeneities between countries, or even regions within
countries, the knowledge and availability of ICM is now
greater than ever before. It is the duty of scientiﬁc soci-
eties such as ESICM to foster the development and the
dissemination of new knowledge. It is our duty to dem-
onstrate that with this new knowledge Intensivists will be
able to improve the outcome of their patients.
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